Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | PI4KA | P42356 | 3/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | ABL2 | P42684 | 2/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516021 | 0.87 | ADORA2A (0.60) | CYP1A2CYP3A4NFKB1THPOBLM | |
| SCHEMBL2727979 | 0.85 | ADORA2A (0.64) | CYP1A2CYP3A4NFKB1THPOBLM | |
| SCHEMBL28902640 | 0.84 | SRC (0.57) | SRCEGFRPI4KBABL1ABL2 | |
| SCHEMBL28902638 | 0.84 | SRC (0.57) | SRCEGFRPI4KBABL1ABL2 | |
| SCHEMBL21138850 | 0.84 | EGFR (0.50) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL29927091 | 0.84 | SRC (0.57) | SRCEGFRPI4KBABL1ABL2 | |
| SCHEMBL21138453 | 0.84 | EGFR (0.50) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL21138452 | 0.84 | EGFR (0.50) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL19731370 | 0.83 | SRC (0.66) | SRCEGFRABL1ABL2 | |
| SCHEMBL14637043 | 0.82 | SRC (0.65) | SRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130345192-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | CYP1A2 4339/4885CYP3A4 4034/4885NFKB1 2288/4885 |
| US-20130345192-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | CYP1A2 4339/4885CYP3A4 4034/4885NFKB1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.